Fungal Infections

NICU Antibiotic Use Rates Declined From 2013 to 2016

September 10, 2018

There was no correlation between the 2016 AUR and either proven infection or necrotizing enterocolitis. However, there was an association between the 2016 regional NICU AUR and surgical volume, mortality rate, and average length of stay

CDC: Greater Awareness of Valley Fever Needed Nationally

August 29, 2018

Seven in 10 patients had another condition diagnosed before coccidioidomycosis testing occurred, of whom the vast majority (83%) were prescribed antibacterial medications, 43% were hospitalized, and 29% had culture-positive coccidioidomycosis.

Prevalence of Antimicrobial-Contraindicated Drug Combo Prescribing Examined

By August 16, 2018

Researchers performed a cross-sectional study that included multiple year pooled data (2003 to 2011) from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department).

Antifungal Use During Pregnancy and Risk of Stillbirth: What's the Link?

By June 13, 2018

Based on the findings, it was concluded that fluconazole use during pregnancy was not associated with significantly increased risks of stillbirth or neonatal death. However, the authors cautioned that the confidence intervals were wide and neither result was statistically significant.

Drug-Induced Chemical Sensitivity After Exposure to Azole Antifungals

By May 04, 2018

His reactions were also triggered by foods such as bananas, apples, and milk.

First-in-Class Antifungal Fast-Tracked for Vulvovaginal Candidiasis

By May 01, 2018

SCY-078 is an investigational antifungal agent that is a semi-synthetic derivative of the natural product enfumafungin.

First Test to ID <i>Candida auris</i> Gets FDA Approval

By April 23, 2018

The Bruker Maldi system is already cleared for use in identifying 333 species or species groups, including 424 bacteria and yeast species.

Large Drop Seen in Infection-Related Post-Transplant Deaths

April 06, 2018

Infectious causes of death and mortality rates for infections for 2 time periods - 1990 to 1999 and 2000 to 2012 - among 3,249 adult recipients of a first kidney transplant were assessed during the study period.

FDA Approves the Use of Luzu Cream in Younger Patients

By February 23, 2018

Luzu, an azole antifungal, is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum.

FDA: New Tool to Help Clinicians Make Appropriate Antibiotic Choices

By December 13, 2017

New website streamlines how FDA updates information used to help health care providers choose an appropriate treatment for a patient's infection.

Perrigo Approved for Generic Mycolog II Cream

By November 28, 2017

Triamcinolone acetonide is mainly effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions.

Antifungal Tablets to Be Discontinued

By November 15, 2017

Novartis Pharmaceuticals has made a business decision to permanently discontinue the product Lamisil Tablets 250mg.

Test Helps Clinicians Select Appropriate Tx for Suspected Wound Infections

By October 05, 2017

Using a simple swab from the infection site, DxWound uses a special transport buffer that preserves the wound microbiome during transit.

FDA Fast Tracks New Oral Antifungal to Treat Valley Fever

By July 13, 2017

VT-1598, an oral fungal CYP51 inhibitor, has shown high potency against pathogens such as molds, yeasts, and multi-drug resistant fungal pathogens (eg, Candida auris).

Addition of Antifungal to Cancer Tx Leads to Nephrotic Syndrome

July 07, 2017

Case report of patient with relapsed Hodgkin's lymphoma treated with everolimus for five years

Therapies Compared for Treating Deadly Fungal Infection in HIV Patients

June 15, 2017

Compared with itraconazole, amphotericin treatment correlated with significantly faster clinical resolution and fungal clearance and with significantly lower rates of relapse and immune reconstitution inflammatory syndrome.

Plant Found to Harbor Drug-Resistant Fungal Pathogen

By May 18, 2017

Results showed that 5 of the 6 bulb packages tested positive for triazole-resistant A. fumigatus.

Meningitis, Encephalitis Caused by Viruses Mostly in the U.S.

By April 20, 2017

Enterovirus was found to be the most common etiology (50.9%), followed by unknown (18.7%), bacterial meningitis (13.9%), herpes simplex virus (8.3%), non-infectious (3.4%), fungal (2.7%), arboviruses (1.1%), and other viruses (0.8%).

Infant's Tongue Lesion Mimics Neoplastic Growth

April 10, 2017

"This case reinforces the role of tissue culture when histology fails to demonstrate a diagnosis and emphasizes the need for efficient communication between the pediatrician, otolaryngologist, and pathologist for timely excision," the authors write.

Thrombotic Microangiopathy Cases Prompt Update to Antifungal Drug Labeling

By January 25, 2017

The labeling for Lamisil (terbinafine hydrochloride) Tablets and Oral Granules has been updated to include a new warning regarding the risk of thrombotic microangiopathy.

Dr. Reddy's Launches Generic Topical Antifungal Cream

By December 06, 2016

Dr. Reddy's Laboratories has announced the launch of Nystatin and Triamcinolone Acetonide Cream, the generic equivalent of Taro Pharmaceutical's Nystatin and Triamcinolone Acetonide Cream, USP 100,000/g 0.1%.

Naftin Labeling Updated with Pediatric Usage Information

By November 29, 2016

The Food and Drug Administration (FDA) has approved new labeling for Naftin (naftifine HCl cream 2%; Merz Pharmaceuticals) adding additional information regarding use in the pediatric population.

CDC Reports on Emerging Pathogenic Fungus in the U.S.

November 04, 2016

The CDC announced an alert in June 2016 requesting all clinicians, laboratory workers, infection control practitioners, and public health authorities report C. auris cases.

Posaconazole Prophylaxis Safe in Routine Clinical Use for Hematological Malignancies

By October 28, 2016

Both the tablet and intravenous (IV) formulations of posaconazole appeared to be safe and effective for primary prophylaxis against invasive fungal infections in patients with hematologic malignancies, according to results of a retrospective cohort study presented at IDWeek 2016.

Novel Treatment for Recurrent Vulvovaginal Candidiasis Gets Fast Track Status

By October 13, 2016

Viamet has announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designation to VT-1161, a novel treatment for recurrant vulvovaginal candidiasis (RVVC).

Does Empirical Micafungin Improve Survival in Critically Ill Patients?

October 07, 2016

No increase in invasive fungal infection-free survival for ICU-acquired sepsis, Candida colonization

Potent Oral Antifungal Granted QIDP Status for Valley Fever

By September 15, 2016

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis, or Valley Fever.

Antifungal-Chemotherapy Drug Interaction Update

By September 13, 2016

The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.

Inhaled Antifungal Granted Orphan Drug Status for Cystic Fibrosis

By August 22, 2016

The Food & Drug Administration has granted Orphan Drug designation to PUR1900 (Pulmatrix) for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF).

New Guidelines on Invasive Aspergillosis Diagnosis, Treatment Released

By July 05, 2016

The Infectious Diseases Society of America (IDSA) announced the release of updated guidelines on the diagnosi sand treatment of major forms of aspergillosis. The full guidelines are published in Clinical Infectious Diseases.